跳至內容

C-26

新增連結
維基百科，自由的百科全書

C-26是在1975年建系的小鼠雜種瘤（英語：Hybridoma technology）細胞系。

歷史

最初於1975年分離自一個6個月大的雌性Balb/c實驗小鼠的結腸雜種瘤組織，研究人員通過在腸上單次應用N-亞硝基-N-甲基尿素（英語：N-Nitroso-N-methylurea）誘導小鼠形成腫瘤來建立C-26腫瘤細胞模型[1]，直至1988年才正式在體外培養中建立C-26細胞系[2]，並且發現C-26細胞具有很高的致瘤性及低的轉移趨勢，而接種C-26細胞的小鼠出現高死亡率的情況[2]。1990年，有研究人員發現在食物攝入量不變的情況下，進行體內植入C-26細胞的小鼠普遍會減輕體重，同時出現低血糖和分泌過多皮質類固醇的現象。C-26細胞不僅會使肝功能出現紊亂，還會引致脂肪、骨骼及肌肉組織的損失，因此是研究惡病體質潛在機制的合適模型。值得注意的是C-26細胞誘導的惡病體質會因接種部位的不同而存在差異[3]。近年，有研究人員在小鼠的側面或背部植入C-26腫瘤細胞的固體片段至體內[4]。

科研用途

癌症方面

目前已將C-26模型用於研究癌症的自然史和抗腫瘤治療。例如研究MMP抑製劑的功效[5]、顯示腫瘤部位的血管生成素利用率降低會阻礙新血管的生成，從而限制腫瘤的生長和轉移[6]。不少研究項目透過將C-26細胞注射到小鼠體內來探究各種當時未解決的問題，例如CXCR3的拮抗作用對抗癌細胞向靶器官發展的潛力[7]、糖皮質激素脂質體製劑的抗腫瘤作用[8]、植入C-26細胞的小鼠接受幾種抗腫瘤藥物時發生的作用[9]，以及間質內激光凝固與阿黴素聯合治療的效果[10]。此外，C-26細胞同時已應用於證明白介素18（英語：Interleukin 18）[11]、白介素27（英語：Interleukin 27）[12]和趨化因子CCL21（英語：CCL21）/SLC的抗腫瘤作用[13]。

參考資料

  1. ^ Corbett, TH; Griswold DP, Jr; Roberts, BJ; Peckham, JC; Schabel FM, Jr. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure.. Cancer research. 1975-09, 35 (9): 2434–9 [2019-12-11]. PMID 1149045. 
  2. ^ 2.0 2.1 Allison, DC; Ridolpho, PF; Anderson, S; Bose, K. Variations in the [3H]thymidine labeling of S-phase cells in solid mouse tumors.. Cancer research. 1985-12, 45 (12 Pt 1): 6010–6 [2019-12-11]. PMID 4063961. 
  3. ^ Tanaka, Y; Eda, H; Tanaka, T; Udagawa, T; Ishikawa, T; Horii, I; Ishitsuka, H; Kataoka, T; Taguchi, T. Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice.. Cancer research. 1990-04-15, 50 (8): 2290–5 [2019-12-11]. PMID 2317817. 
  4. ^ Samuels, SE; McLaren, TA; Knowles, AL; Stewart, SA; Madelmont, JC; Attaix, D. Liver protein synthesis stays elevated after chemotherapy in tumour-bearing mice.. Cancer letters. 2006-07-28, 239 (1): 78–83 [2019-12-11]. PMID 16140458. doi:10.1016/j.canlet.2005.07.026. 
  5. ^ Lozonschi, L; Sunamura, M; Kobari, M; Egawa, S; Ding, L; Matsuno, S. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models.. Cancer research. 1999-03-15, 59 (6): 1252–8 [2019-12-11]. PMID 10096556. 
  6. ^ Melani, C; Stoppacciaro, A; Foroni, C; Felicetti, F; Caré, A; Colombo, MP. Angiopoietin decoy secreted at tumor site impairs tumor growth and metastases by inducing local inflammation and altering neoangiogenesis.. Cancer immunology, immunotherapy : CII. 2004-07, 53 (7): 600–8 [2019-12-11]. PMID 14985859. doi:10.1007/s00262-004-0500-5. 
  7. ^ Cambien, B; Karimdjee, BF; Richard-Fiardo, P; Bziouech, H; Barthel, R; Millet, MA; Martini, V; Birnbaum, D; Scoazec, JY; Abello, J; Al Saati, T; Johnson, MG; Sullivan, TJ; Medina, JC; Collins, TL; Schmid-Alliana, A; Schmid-Antomarchi, H. Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism.. British journal of cancer. 2009-06-02, 100 (11): 1755–64 [2019-12-11]. PMID 19436305. doi:10.1038/sj.bjc.6605078. 
  8. ^ Schiffelers, RM; Banciu, M; Metselaar, JM; Storm, G. Therapeutic application of long-circulating liposomal glucocorticoids in auto-immune diseases and cancer.. Journal of liposome research. 2006, 16 (3): 185–94 [2019-12-11]. PMID 16952873. doi:10.1080/08982100600851029. 
  9. ^ Lupu, CM; Eisenbach, C; Kuefner, MA; Schmidt, J; Lupu, AD; Stremmel, W; Encke, J. An orthotopic colon cancer model for studying the B7-H3 antitumor effect in vivo.. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2006-05, 10 (5): 635–45 [2019-12-11]. PMID 16713537. doi:10.1007/bf03239969. 
  10. ^ Veenendaal, LM; van Hillegersberg, R; Smakman, N; van der Bilt, JD; van Diest, PJ; Kranenburg, O; Borel Rinkes, IH. Synergistic effect of interstitial laser coagulation and doxorubicin in a murine tumor recurrence model of solitary colorectal liver metastasis.. Annals of surgical oncology. 2006-02, 13 (2): 168–75 [2019-12-11]. PMID 16424982. doi:10.1245/ASO.2006.03.076. 
  11. ^ Leng, J; Zhang, L; Yao, H; Cao, X. Antitumor effects of interleukin-18 gene-modified hepatocyte cell line on implanted liver carcinoma.. Chinese medical journal. 2003-10, 116 (10): 1475–9 [2019-12-11]. PMID 14570604. 
  12. ^ Hisada, M; Kamiya, S; Fujita, K; Belladonna, ML; Aoki, T; Koyanagi, Y; Mizuguchi, J; Yoshimoto, T. Potent antitumor activity of interleukin-27.. Cancer research. 2004-02-01, 64 (3): 1152–6 [2019-12-11]. PMID 14871851. doi:10.1158/0008-5472.can-03-2084. 
  13. ^ Hisada, M; Yoshimoto, T; Kamiya, S; Magami, Y; Miyaji, H; Yoneto, T; Tamada, K; Aoki, T; Koyanagi, Y; Mizuguchi, J. Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT.. Cancer gene therapy. 2004-04, 11 (4): 280–8 [2019-12-11]. PMID 15002032. doi:10.1038/sj.cgt.7700676. 

外部連結

取自 "https://zh.wikipedia.org/w/index.php?title=C-26&oldid=70122837"